ReachMD
Be part of the knowledge.™ACC Action Center
Welcome to the ACC Action Center, bringing you the latest updates from the 2023 American College of Cardiology’s Annual Scientific Session & Expo, hosted in partnership with the World Congress of Cardiology. This collection will highlight emerging clinical data and explore the latest practice-changing advances in the field of cardiology.
Episodes 1-15 of 40
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC Action CenterEffects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
ACC Action CenterTargeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
ACC Action CenterLong-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Promising results for self-expanding TAVR device in trial with mostly women
ACC Action CenterPromising results for self-expanding TAVR device in trial with mostly women
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
ACC Action CenterAngiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Preventive PCI versus only optimal medical therapy for vulnerable plaques
ACC Action CenterPreventive PCI versus only optimal medical therapy for vulnerable plaques
Promising results for APOC3 ASO in familial chylomicronemia syndrome
ACC Action CenterPromising results for APOC3 ASO in familial chylomicronemia syndrome
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC Action CenterIncreasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Self-assessment on statin eligibility without prescription using a web app
ACC Action CenterSelf-assessment on statin eligibility without prescription using a web app
More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
ACC Action CenterMore than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
Stopping aspirin after 1 month DAPT in ACS patients after stenting
ACC Action CenterStopping aspirin after 1 month DAPT in ACS patients after stenting
Head-to-head comparison of two TAVR devices in patients with aortic stenosis and small aortic annuli
ACC Action CenterHead-to-head comparison of two TAVR devices in patients with aortic stenosis and small aortic annuli
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
ACC Action CenterAPOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
ACC Action CenterNo improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
ACC Action CenterEarly aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
